Full data presented Tuesday afternoon from the Phase III Clarity AD trial show Eisai and Biogen’s lecanemab has a favorable safety profile in patients with Alzheimer’s disease.
Tag Archive for: Amyloid-related imaging abnormalities (ARIA)
One day ahead of a data presentation at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference, Science reported a second patient death has been linked to Eisai and Biogen’s lecanemab.
An investigator in the Phase III trial for Biogen and Eisai’s experimental Alzheimer’s drug lecanemab is attributing a patient’s death to the drug.
